局部罗氟司特治疗斑块型银屑病。

Q1 Medicine

Skin therapy letter Pub Date : 2023-09-01

Ashley O'Toole, Melinda Gooderham

{"title":"局部罗氟司特治疗斑块型银屑病。","authors":"Ashley O'Toole, Melinda Gooderham","doi":"","DOIUrl":null,"url":null,"abstract":"Roflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials.","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"28 5","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Topical Roflumilast for Plaque Psoriasis.\",\"authors\":\"Ashley O'Toole, Melinda Gooderham\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Roflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials.\",\"PeriodicalId\":21829,\"journal\":{\"name\":\"Skin therapy letter\",\"volume\":\"28 5\",\"pages\":\"1-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skin therapy letter\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin therapy letter","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

罗氟司特是一种高选择性磷酸二酯酶-4抑制剂，用于治疗斑块型银屑病。经美国食品药品监督管理局和加拿大卫生部批准用于青少年和成人的0.3%罗氟司特局部乳膏已被证明具有疗效和耐受性。它是非甾体的，每天给药一次，药效很强，具有独特的递送配方。它可以用于大多数身体部位，包括敏感的原始区域和面部。在此，我们回顾了临床试验中证明的0.3%罗氟司特乳膏的安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Topical Roflumilast for Plaque Psoriasis.

Roflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Skin therapy letter Medicine-Medicine (all)

CiteScore

2.80

自引率

0.00%

发文量

期刊介绍： The premier international journal on the latest advances, techniques and practice in conservation and restoration from around the world.